- Home
- SGLY vs DRMA Comparison
SGLY vs DRMA Comparison
Compare SGLY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- DRMA
- Stock Information
- Founded
- SGLY 2001
- DRMA 2014
- Country
- SGLY United States
- DRMA United States
- Employees
- SGLY N/A
- DRMA N/A
- Industry
- SGLY
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- DRMA Health Care
- Exchange
- SGLY Nasdaq
- DRMA Nasdaq
- Market Cap
- SGLY 3.9M
- DRMA 4.5M
- IPO Year
- SGLY 2008
- DRMA 2021
- Fundamental
- Price
- SGLY $1.03
- DRMA $0.60
- Analyst Decision
- SGLY
- DRMA Strong Buy
- Analyst Count
- SGLY 0
- DRMA 1
- Target Price
- SGLY N/A
- DRMA $3.00
- AVG Volume (30 Days)
- SGLY 67.2K
- DRMA 94.5K
- Earning Date
- SGLY 08-26-2025
- DRMA 08-06-2025
- Dividend Yield
- SGLY N/A
- DRMA N/A
- EPS Growth
- SGLY N/A
- DRMA N/A
- EPS
- SGLY N/A
- DRMA N/A
- Revenue
- SGLY $2,172,036.00
- DRMA N/A
- Revenue This Year
- SGLY N/A
- DRMA N/A
- Revenue Next Year
- SGLY N/A
- DRMA N/A
- P/E Ratio
- SGLY N/A
- DRMA N/A
- Revenue Growth
- SGLY N/A
- DRMA N/A
- 52 Week Low
- SGLY $0.54
- DRMA $0.57
- 52 Week High
- SGLY $7.65
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- SGLY 51.57
- DRMA 29.24
- Support Level
- SGLY $1.02
- DRMA $0.57
- Resistance Level
- SGLY $1.16
- DRMA $0.63
- Average True Range (ATR)
- SGLY 0.08
- DRMA 0.04
- MACD
- SGLY -0.01
- DRMA -0.01
- Stochastic Oscillator
- SGLY 50.00
- DRMA 11.55
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.